Log in or Sign up for Free to view tailored content for your specialty!
Myeloproliferative Neoplasms News
Myeloproliferative neoplasm risk among U.S. veterans increases over time
Risk for myeloproliferative neoplasms among U.S. veterans increased significantly over time, according to retrospective study results.
Spouses of people with cancer more likely to attempt, die of suicide
Spouses of people with cancer exhibited significantly higher risk for attempted suicide and suicide death than those whose spouses had not been diagnosed with cancer, according to a nationwide cohort study in Denmark.
FDA reduces risk reporting for CAR T cells to ‘minimize the burden’ on providers
FDA has scaled back its Risk Evaluation and Mitigation Strategy reporting requirements for providers of chimeric antigen receptor T-cell therapies.
Log in or Sign up for Free to view tailored content for your specialty!
VIDEO: Targeted strategies, other future research in myeloproliferative neoplasms
In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, discusses what she would like to see in the future of myleoproliferate neoplasms care and management.
VIDEO: Developing curative strategies shows unmet need in myeloproliferative neoplasms
In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, highlights unmet needs in myeloproliferate neoplasms care and management.
VIDEO: JAK inhibitors may help improve quality of life in myeloproliferative neoplasms
In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, explains why it is important to consider how myeloproliferative neoplasms treatment will affect a patient's quality of life.
VIDEO: Approaching treatment in myeloproliferative neoplasms varies by patient
In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, discussed the different approaches to treating different types of MPNs, like myelofibrosis, essential thrombocythemia and polycythemia vera.
VIDEO: Recent developments in myeloproliferative neoplasms
In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, highlighted recent developments and available treatments in myeloproliferative neoplasms care.
ASH to present honorific awards to ‘visionary’ hematologists
Several hematologists will be honored during this year’s ASH Annual Meeting.
New approach ‘redefining what is a suitable donor’ for stem cell transplant
CHICAGO — Interim results from a phase 2 study showed positive survival outcomes for individuals who underwent peripheral blood stem cell transplantation for hematologic malignancies.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read